Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 7,084 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Prostatic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Melanoma, Leukemia
Interventions: Interactive Voice Response (IVR) Reminders; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 21 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Breast Cancer, Kidney Cancer, Lung Cancer
Interventions: interleukin-4 PE38KDEL cytotoxin; Biological
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 2
States / cities: Tucson, Arizona • Los Angeles, California

Conditions: Breast Cancer
Interventions: Abraxane, Carboplatin, Avastin; Drug
Lead sponsor: William Sikov MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 5
States / cities: Bridgeport, Connecticut • New Haven, Connecticut • Providence, Rhode Island

Conditions: Breast Neoplasms, Neoplasms, Hormone-dependent
Interventions: atamestane, toremifene, letrozole, aromatase inhibition, hormone therapy, endocrine therapy, antiestrogen therapy; Drug · Procedure
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 865 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 17
States / cities: Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more

Conditions: Breast Cancer
Interventions: questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: NSCLC, Breast Cancer
Interventions: Poziotinib; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Long Beach, California • Hattiesburg, Mississippi • New York, New York + 2 more

Conditions: Breast Neoplasms
Interventions: Sentinel Lymph Node Biopsy; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pregnancy, Cancer, Cancer in Pregnancy, Gestational Breast Cancer, Pregnancy Related
Interventions: Not listed
Lead sponsor: Cooper Norcross Health; Other
Eligibility: Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2028
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Breast Cancer
Interventions: PTK787, Trastuzumab; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 8
States / cities: Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more

Conditions: Breast Cancer, Cardiovascular Diseases
Interventions: Patient Navigation Program, Quality-of-Life (QOL) Assessment, Survey Administration; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Breast Cancer, Survivorship, Treatment Compliance, Treatment Adherence, Treatment Refusal
Interventions: Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 11
States / cities: Boston, Massachusetts • Brighton, Massachusetts • Concord, Massachusetts + 7 more

Conditions: Breast Cancer
Interventions: IT System; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6,730 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer, Non-squamous Non-small Cell Lung Cancer
Interventions: [F-18]RGD-K5; Drug
Lead sponsor: Siemens Molecular Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Irvine, California • Los Angeles, California • Newark, New Jersey + 2 more

Conditions: Breast Cancer
Interventions: Educational counseling intervention; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Carcinoma, Colon Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions: Electronic Health Record Review, Questionnaire Administration, Behavioral Intervention; Other · Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 19 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Sequim, Washington

Conditions: Breast Carcinoma
Interventions: Electronic Health Record Review, Medical Device Usage and Evaluation, Meditation Therapy, Survey Administration; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Breast Cancer
Interventions: Sorafenib, Ixabepilone; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 15
States / cities: Fort Myers, Florida • Terre Haute, Indiana • Louisville, Kentucky + 10 more

Conditions: TNBC - Triple-Negative Breast Cancer, TNBC, Early Stage Triple-Negative Breast Carcinoma
Interventions: Live biotherapeutic product: MO-03 1 capsule PO BID; Drug
Lead sponsor: Yuan Yuan; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 3
States / cities: Beverly Hills, California • Tarzana, California • Torrance, California

Conditions: Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: Bevacizumab, Erlotinib Hydrochloride, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
Interventions: FPA150, Pembrolizumab; Biological
Lead sponsor: Five Prime Therapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 13
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 10 Years to 50 Years · Female only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Breast Cancer
Interventions: Rucaparib, Radiotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 8
States / cities: Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER+ Breast Cancer, Lobular Breast Carcinoma
Interventions: Neoadjuvant endocrine therapy; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer
Interventions: cisplatin, gemcitabine hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2006
U.S. locations: 19
States / cities: Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 16 more

Search by objective public record fields.

Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR

Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy

Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

Patient Care Outreach, Navigation, Technology and Support 2.0

Culturally Aware AET Non-Initiation Intervention

A Mammography FastTrack Program in Increasing the Number of Women Undergoing Breast Cancer Screening

Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug

Enhancing Connections: Helping the Mother With Breast Cancer Support Her Child

Clinical Outcomes for Offering Genetic Testing in a Tiered Approach

MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

FPA150 in Patients With Advanced Solid Tumors

Biomarkers for Breast Cancer Risk in African American Women

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer